The Next-Generation Antibody Players
This article was originally published in Start Up
Executive Summary
A host of companies are vying to develop new and improved antibodies. Technologies span the gamut from improving ADCC effector function to stripping away components of traditional antibodies to create leaner molecules that may be cheaper to manufacture and eaiser to deliver orally. These start-ups remain product focused, eschewing the platform technology model. Pharmaceutical and established biotechnology companies are eager to get their hands on the technologies, causing a flurry of deal-making in the last year.
You may also be interested in...
The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets
An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.
The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets
An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.
Merck Announces Major FOB Initiative With Its New Business Unit
Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.